Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong William Goodman?

William G. Goodman

Clinical Research Director

Amgen Inc.

HQ Phone:  (805) 447-1000

Direct Phone: (805) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Amgen Inc.

One Amgen Center Dr.

Thousand Oaks, California,91320

United States

Company Description

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to u...more

Background Information

Employment History

Professor of Medicine, Director

UCLA


Affiliations

American Society for Bone and Mineral Research

Member


Journal of the American Society of Nephrology

Member, Editorial Boards


American Society of Nephrology

Member


National Kidney Foundation Inc

Member of the Scientific Advisory Council


Kidney International

Member, Editorial Boards


International Society of Nephrology

Member


Education

MD


medical degree

The Ohio State University College of Medicine


Web References(38 Total References)


Dialysis Outcomes and Practice Patterns Study (DOPPS) -- DOPPS Task Forces, Scientific Advisory Committee

www.dopps.org [cached]

Bill Goodman, MD
Amgen, Inc., Thousand Oaks, CA USA


www.francefoundation.com

William Goodman, MDWilliam G. Goodman, MD, has served as a speaker for Abbott Laboratories, Amgen, Genzyme, and Kirin Pharmaceuticals.He has also served as a consultant for Amgen, Quest-Nichols, Genzyme, and Kirin.Dr. Goodman owns stock in Amgen and Abbott Laboratories.As Professor of Medicine at UCLA, Dr. Goodman contributed to the CRESCENTÔ content.Effective September 2006, Dr. Goodman will be employed at Amgen.


Mednet - CME, CHE | Management of Bone and Mineral Abnormalities in Chronic Kidney Disease

www.mednet.ca [cached]

“This decline occurs before there is any elevation in serum phosphorus,� Dr. William Goodman, Professor of Medicine, David Geffen School of Medicine, noted.
Abnormalities in vitamin D metabolism in turn adversely affect intestinal calcium transport. Thus, in Dr. Goodman’s view, elevations in PTH in early-stage CKD is an appropriate physiological response that helps maintain serum calcium levels. In both healthy individuals as well as in patients with mild to moderate CKD, phosphorus loading impairs the kidney’s production of 1,25-dihydroxyvitamin D3, while restricting phosphorus will increase its production. The literature suggests that even if phosphorus level is normal, restricting phosphorus in the diet or through the use of phosphate binders will drive up 1,25-dihydroxy-vitamin D3 production and help prevent bone disease. Increases in 1,25-dihydroxyvitamin D3 levels correspond with subsequent reductions in plasma PTH levels, “so it is the change in circulating 1,25-dihydroxyvitamin D3 levels that mediates the reduction in PTH, not phosphorus per se,â€� Dr. Goodman indicated. He also argued that patients with earlier-stage CKD are fundamentally different than those on dialysis, largely because they still have residual kidney function and they can excrete phosphorus. In patients who have mild to moderate CKD, serum phosphorus levels are usually normal, while serum calcium levels are typically in the lower range of normal, he added; and the fact that patients with mild CKD excrete relatively little calcium is a sign that the kidney is trying to conserve calcium. “I’m not arguing with the fact that phosphate restriction and phosphate binders are appropriate when serum phosphate levels are elevated,â€� Dr. Goodman stated. Data supporting a non-calcium-based phosphate binder strategy are limited but one prospective studyâ€"the “treat-to-goalâ€� trialâ€"showed that vascular calcification did not worsen over one year of follow-up in dialysis patients treated with sevelamer, whereas it did progress in patients treated with a calcium phosphate binder. “Theoretically, the use of lanthanum carbonate might have a similar beneficial effect because it is also calcium-free,â€� Dr. Goodman indicated, although this has not yet been demonstrated in a prospective trial. However, he stated that the choice of a phosphate binding agent could influence progression of calcification once it is present, even though it is not clear how vascular calcification develops in the first place. “Your choice of phosphate binder is going to be influenced very significantly by other biochemical abnormalities,â€� Dr. Goodman cautioned. In an interview, Dr. Goodman also suggested that this agent might be equivalent in potency to the old aluminum-containing binders and more potent than calcium carbonate nor calcium acetate.


Faculty

www.activatekidneycare.com [cached]

William G. Goodman, MDWilliam G. Goodman, MD, is Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), where he is Director of the Bone Histology Laboratory at UCLA Medical Center.After earning his medical degree from The Ohio State University College of Medicine in Columbus, Dr. Goodman completed an internship and residency in internal medicine at Henry Ford Hospital in Detroit, Michigan, where he served as chief resident.Following residency, Dr. Goodman completed a fellowship in nephrology at the University of Washington in Seattle.He is board-certified in internal medicine and nephrology.Dr. Goodman's research on secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification in patients on dialysis has been published in numerous peer-reviewed journals, including The New England Journal of Medicine, Kidney International, American Journal of Kidney Disease, and Pediatric Nephrology.He has contributed to more than 20 book chapters and 150 abstracts.He sits on the editorial boards of Journal of the American Society of Nephrology and Kidney International and serves as a reviewer for a number of scientific publications including The Journal of Clinical Investigation, The New England Journal of Medicine, and The Lancet, among others.Dr. Goodman's commitment to his field extends to the community where he has served as a member of the Scientific Advisory Council of the National Kidney Foundation of Southern California and as a member of the Program Committee for the NKF spring clinical meetings.He is a 20-year member of many professional organizations, including the American Society of Nephrology, the International Society of Nephrology, and The American Society for Bone and Mineral Research.


NKF's 2005 Spring Clinical Meetings - Faculty

www.kidney.org [cached]

William Goodman, MD David Geffen School of Medicine at UCLA


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory